BioXcel Therapeutics (BTAI) Tops Q3 EPS by 19c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q3 EPS of ($0.32), $0.19 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $210 thousand versus the consensus estimate of $1.33 million.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Deere (DE) PT Lowered to $570 at JPMorgan Ahead of Earnings
• StablecoinX reports Q2 2026 results with $34.2M net loss